Smith Salley Wealth Management Acquires 713 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Smith Salley Wealth Management raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,106 shares of the medical research company’s stock after buying an additional 713 shares during the quarter. Smith Salley Wealth Management’s holdings in IQVIA were worth $2,183,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Farallon Capital Management LLC lifted its position in IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares in the last quarter. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc raised its position in IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in IQVIA by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after acquiring an additional 11,715 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. Robert W. Baird cut their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Trading Down 0.2 %

Shares of NYSE:IQV opened at $197.25 on Friday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The business has a 50 day moving average of $200.09 and a 200-day moving average of $221.29. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $35.80 billion, a PE ratio of 25.89, a P/E/G ratio of 2.09 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.